LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | A443654 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 10311 | 11155 | 0.9243 | 0.9108 |
MCF 10A | OSI-027 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 10571 | 11155 | 0.9476 | 0.9382 |
MCF 10A | XMD11-85h | 0.04 | uM | LJP6 | 72 | hr | 1694 | 10890 | 11155 | 0.9762 | 0.9720 |
MCF 10A | HG-6-64-01 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 11289 | 11155 | 1.0120 | 1.0141 |
MCF 10A | WH-4-025 | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11668 | 11155 | 1.0460 | 1.0542 |
MCF 10A | WZ-4-145 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 10404 | 11155 | 0.9327 | 0.9206 |
MCF 10A | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 1694 | 10283 | 11155 | 0.9218 | 0.9078 |
MCF 10A | Brivanib | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11133 | 11155 | 0.9980 | 0.9977 |
MCF 10A | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11151 | 11155 | 0.9996 | 0.9996 |
MCF 10A | BX-912 | 0.04 | uM | LJP5 | 72 | hr | 1694 | 10337 | 11155 | 0.9267 | 0.9135 |
MCF 10A | Canertinib | 0.04 | uM | LJP6 | 72 | hr | 1694 | 9108 | 11155 | 0.8165 | 0.7836 |
MCF 10A | Celastrol | 0.04 | uM | LJP6 | 72 | hr | 1694 | 11896 | 11155 | 1.0664 | 1.0783 |
MCF 10A | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1694 | 10131 | 11155 | 0.9082 | 0.8917 |
MCF 10A | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 387 | 11155 | 0.0347 | -0.1382 |
MCF 10A | CHIR-99021 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 11560 | 11155 | 1.0363 | 1.0428 |
MCF 10A | CP724714 | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11221 | 11155 | 1.0059 | 1.0069 |
MCF 10A | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11482 | 11155 | 1.0293 | 1.0345 |
MCF 10A | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 1694 | 10879 | 11155 | 0.9752 | 0.9708 |
MCF 10A | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1694 | 10543 | 11155 | 0.9451 | 0.9353 |
MCF 10A | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 1694 | 8979 | 11155 | 0.8049 | 0.7700 |
MCF 10A | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1694 | 6203 | 11155 | 0.5561 | 0.4766 |
MCF 10A | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1694 | 10366 | 11155 | 0.9292 | 0.9166 |
MCF 10A | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11228 | 11155 | 1.0065 | 1.0076 |
MCF 10A | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1694 | 10798 | 11155 | 0.9680 | 0.9622 |
MCF 10A | Foretinib | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11930 | 11155 | 1.0694 | 1.0819 |